uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Pharmaco-economics of levosimendan in cardiology: A European perspective
Univ Helsinki, Cent Hosp, Helsinki, Finland..
St Marien Krankenhaus, Kardiol Angiol & Internist Intens Med, Siegen, Germany..
Attiko Teaching Hosp, Univ Cardiol Clin 2, Athens, Greece..
Rabin Med Ctr, Heart Failure Unit, Petah Tiqwa, Israel.;Rabin Med Ctr, Heart Transplant Clin, Petah Tiqwa, Israel..
Show others and affiliations
2015 (English)In: International Journal of Cardiology, ISSN 0167-5273, E-ISSN 1874-1754, Vol. 199, 337-341 p.Article in journal (Refereed) Published
Abstract [en]

Introduction: Heart failure places a significant economic burden on health care. Acute heart failure requires hospitalization and often frequent re-hospitalization in expensive wards where vasoactive rescue therapy is often added on top of standard medications. In these lean times, there is a growing need for cost-effective therapeutic options that supply superior support and in addition shorten the length of stay in hospital and reduce re-hospitalization rates. The inodilator levosimendan represents the latest addition to the vasoactive treatments of acute heart failure patients, and it appears to meet these expectations. Our aim was to answer the question whether the treatment efficacy of levosimendan - when selected as therapy for patients hospitalized for acute heart failure - brings savings to hospitals in various European countries representing different economies. Methods and results: We took a conservative approach and selected some a fortiori arguments to simplify the calculations. We selected seven European countries to represent different economies: Italy, Spain, Greece, Germany, Sweden, Finland and Israel. Data on the costs of medications and on the cost per day were collected and fed in a simple algorithm to detect savings. These saving varied from country to country, from a minimum of (sic)0.50 in Germany to a maximum of (sic)354.64 in Sweden. Conclusions: The use of levosimendan as a therapy for patients hospitalized for acute heart failure provides a net saving to hospitals driven by a reduction in the length of hospital stay. This finding is true in each of the countries considered in this study.

Place, publisher, year, edition, pages
2015. Vol. 199, 337-341 p.
Keyword [en]
Acute heart failure, Hospitalization, Length of stay, Inodilators, Costs, Benefits
National Category
Cardiac and Cardiovascular Systems
URN: urn:nbn:se:uu:diva-264594DOI: 10.1016/j.ijcard.2015.07.049ISI: 000361150100070PubMedID: 26241640OAI: oai:DiVA.org:uu-264594DiVA: diva2:866083
Available from: 2015-10-30 Created: 2015-10-15 Last updated: 2015-10-30Bibliographically approved

Open Access in DiVA

fulltext(405 kB)62 downloads
File information
File name FULLTEXT01.pdfFile size 405 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Wikström, Gerhard
By organisation
In the same journal
International Journal of Cardiology
Cardiac and Cardiovascular Systems

Search outside of DiVA

GoogleGoogle Scholar
Total: 62 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 208 hits
ReferencesLink to record
Permanent link

Direct link